KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $2.0 billion.

  • Regeneron Pharmaceuticals' Other Non-Current Liabilities rose 2847.14% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 2847.14%. This contributed to the annual value of $2.0 billion for FY2025, which is 2847.14% up from last year.
  • Regeneron Pharmaceuticals' Other Non-Current Liabilities amounted to $2.0 billion in Q4 2025, which was up 2847.14% from $1.9 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $2.0 billion in Q4 2025 and a low of $571.5 million during Q1 2021
  • Its 5-year average for Other Non-Current Liabilities is $1.0 billion, with a median of $778.6 million in 2022.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 965.89% in 2022, then soared by 10412.95% in 2024.
  • Regeneron Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $680.2 million in 2021, then fell by 6.2% to $638.0 million in 2022, then soared by 33.87% to $854.1 million in 2023, then soared by 83.98% to $1.6 billion in 2024, then increased by 28.47% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q4 2025, $1.9 billion for Q3 2025, and $1.7 billion during Q2 2025.